Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer.
Li-Yue SunWen-Jian CenWen-Ting TangYa-Kang LongXin-Hua YangXiao-Meng JiJiao-Jiao YangRen-Jing ZhangFang WangJian-Yong ShaoZi-Ming DuPublished in: Cancer medicine (2021)
The combination of TMB with smoking status might be a potential predictor for the efficacy of combination immunotherapy in advanced NSCLC.